Evidence suggests that the pruritus of cholestasis is,
|
|
- Kristian Miles
- 5 years ago
- Views:
Transcription
1 Gabapentin in Patients With the Pruritus of Cholestasis: A Double-Blind, Randomized, Placebo-Controlled Trial Nora V. Bergasa, 1 Monnie McGee, 2 Iona H. Ginsburg, 3 and Danielle Engler 3 Pruritus is defined as the second order of nociception, the first being pain; thus, there is a rationale to study gabapentin, a drug that increases the threshold to experience nociception. The aim of this double-blind, randomized, placebo-controlled trial was to study the effect of gabapentin on the perception of pruritus and its behavioral manifestation, scratching, in cholestasis. The participants were 16 women with chronic liver disease and chronic pruritus. Hourly scratching activity (HSA) was continuously recorded for up to 48 hours at baseline and on treatment for at least 4 weeks in an inpatient setting. The perception of pruritus was assessed by interviews and by a visual analog score (VAS) of pruritus recorded every hour while patients were awake. Patients were randomized to the study drug (gabapentin or placebo) at a starting dose of 300 mg orally per day in divided doses to a maximum of 2,400 mg or until relief from pruritus. Gabapentin was associated with an increase in mean HSA, in contrast to the placebo, which was associated with a decrease. The mean VAS decreased significantly among those taking the placebo and in some patients on gabapentin. In conclusion, gabapentin did not provide a significant therapeutic advantage over the placebo; in fact, it was associated with an increase in the perception of pruritus and in HSA in some patients. (HEPATOLOGY 2006;44: ) Evidence suggests that the pruritus of cholestasis is, in part, mediated by neurotransmitters/neuromodulators, including endogenous opioids. 1 The idea of altered neurotransmission in the mediation of the pruritus of cholestasis has led to the study of drugs with neuropsychiatric effects for the treatment of this type of pruritus. 2 As pruritus is a nociceptive stimulus, 3 there is a rationale to study gabapentin, a drug that increases the threshold of nociception. 4,5 Furthermore, gabapentin was reported to be effective in the treatment of brachioradial pruritus. 6 These reports were the basis for the present study of the effect of gabapentin on the pruritus of cholestasis. Patients and Methods The study was approved by the institutional review board of Columbia University College of Physicians and From the 1 State University of New York at Downstate, Brooklyn, NY; 2 Southern Methodist University, Dallas, TX; and 3 Columbia University, New York, NY Received March 26, 2006; accepted August 2, Supported by 1RO3DK A1 and GCRC grant RR This trial has been registered at and its registration number is Address reprint requests to: Nora V. Bergasa, M.D., Division of Hepatology, State University of New York at Downstate, 450 Clarkson Avenue, Box 50, Brooklyn, NY Nora.Bergasa@downstate.edu. Copyright 2006 by the American Association for the Study of Liver Diseases. Published online in Wiley InterScience ( DOI /hep Potential conflict of interest: Nothing to report. Surgeons and of the New York Presbyterian Hospital, where it was conducted. All patients signed a consent form prior to entry into the study. A physician with expertise in liver disease was the study monitor. The recruitment rate was less than anticipated; thus, after a 3-year period we stopped recruiting for the study. Participants. Fifty-six patients with chronic liver disease and chronic pruritus were evaluated as potential candidates for the study. Twenty-six patients were found to be eligible. Of these, 9 did not wish to participate after the index visit or follow-up visits, and one did not return for further evaluation. Thus, 16 patients were enrolled in the study (Fig. 1). The study group consisted of 16 women whose median age was 49 years (range years). Nine patients (patients 1, 2, 4, 6, 9, 10, 12, 15, and 16) had primary biliary cirrhosis (PBC), one patient (patient 3) had primary sclerosing cholangitis (PSC), and 6 patients (patients 5, 7, 8, 11, 13, and 14) had chronic liver disease secondary to infection with the hepatitis C virus. The duration of the pruritus was 1-12 years, except in patient 11, for whom it was 4 months. All the patients reported it interfered with their quality of life. All patients had a serum hepatic panel consistent with cholestasis, with a median serum alkaline phosphatase activity of 397 U/L (range U/L, normal U/L). The drugs used to treat the pruritus, including cholestyramine, antihistamines, naltrexone, rifampicin, ser- 1317
2 1318 BERGASA ET AL. HEPATOLOGY, November 2006 Fig. 1. Potential candidates for participation in the study, reasons for exclusion from randomization, and subjects randomized. traline, and ondansetron, alone or in combination, had not provided satisfactory relief. Two patients who had chronic hepatitis C (patients 5 and 14) were taking ursodeoxycholic acid without any relief of pruritus. Study Design. The study was a double-blind, randomized, placebo-controlled trial with a treatment phase of 4 weeks duration. The trial was designed to study patients aged years with chronic pruritus secondary to liver disease. The exclusion criteria were history of hepatic encephalopathy, ascites, history of variceal bleeding, malignancy, inability to practice contraception, pregnancy, creatinine greater than 1.7 mg/dl, hemoglobin less than 10 g/dl, status of post liver transplantation, and infection with the human immunodeficiency virus. At baseline, the principal investigator took a complete history and performed a physical examination, and laboratory tests including a complete blood count, coagulation and comprehensive metabolic panels, and, when appropriate, a pregnancy test were obtained. To determine if depression existed at baseline, a psychiatrist (I.H.G.) evaluated the patients prior to their receiving the study drug, using the Hamilton Depression Rating Scale, a measure of the severity of current depression, 7 and the Structured Clinical Interview Questionnaire (SCID) for DSM IV, Axis I Disorders, an interview measure for the diagnosis of depression and anxiety syndromes. 8 A dermatologist (D.E.) examined the patients to exclude dermatological causes of the pruritus. Drugs prescribed for the treatment of pruritus were discontinued 5 days before the collection of baseline data and were not restarted during the study, as was done in previous studies Patients who took antihistamines to sleep were kept on those drugs. The data were collected in the inpatient and outpatient units of the General Clinical Research Center (GCRC) of New York Presbyterian Hospital. Each patient had 2 hospitalizations, at baseline and while on treatment. The patients were contacted by telephone by the principal investigator at weeks 1 and 3 after randomization to assess how they were tolerating the drug and to adjust the dose, and they were evaluated in person at week 2 with an exam and blood work. Evaluation of the Perception of Pruritus and Scratching Activity. The perception of pruritus was assessed every hour while the patients were awake with a 10-cm visual analog scale from which a visual analog score was derived, as previously described A scratching activity monitoring system specifically designed to record scratching behavior independent of gross body movement 13 and successfully utilized in several previous clinical trials was used Continuous recording of scratching activity was performed over one or two 24- hour periods (depending on the patient s availability), beginning on the morning of day 2 of admission and ending on the morning of day 4 during both the baseline and on-treatment hospitalizations. After the baseline HSA and VASs were collected, subjects were randomized to receive the placebo or the active drug according to a randomization code generated and kept at the research pharmacy. After at least 4 weeks on the study drug subjects were admitted to the GCRC for data collection, after which the code was broken. On completion of the treatment period, patients who had been randomized to the placebo were offered gabapentin for 4 weeks to provide them with possible relief; patients who had been randomized to gabapentin and who reported relief received a 1-week supply of the drug, to be continued by the referring physician, as per protocol. Each patient documented on a form the number of capsules taken and any effects associated with their intake. The forms were collected and reviewed on follow-up appointments. Study Drug. Gabapentin was obtained from the manufacturer (Parke Davis Pharmaceuticals, Ltd., Vega Baja, Puerto Rico) and packaged at the research pharmacy in 100- and 300-mg maroon capsules, like those of the placebo. Under code, the study drug was started at 100 mg by mouth 3 times a day for 3 days, to be increased, if necessary and in the absence of side effects, by 300 mg every 3 days to a maximum of 2,400 mg daily in divided doses. Patients 1-8 received a starting dose of the study medication of 300 mg once a day; however, because of reported vomiting by 2 patients, one of whom was a study
3 HEPATOLOGY, Vol. 44, No. 5, 2006 BERGASA ET AL participant (patient 8), after a dose of 300 mg of gabapentin, the protocol was amended to a starting dose of 100 mg, as described previously. Statistical Methods. Exploratory descriptive statistics and graphics were analyzed according to whether patients were randomized to gabapentin (i.e., the gabapentin group) or to placebo (i.e., the placebo group), with those in each group further assessed both pre- and on-treatment, making 4 categories. Mean differences in measurements were determined by subtracting each on-treatment value from each pretreatment value for each subject and calculating the mean of all the differences. A positive mean difference indicates that, on average, the pretreatment mean HSA and the pretreatment mean VAS were greater than the corresponding on-treatment values. Paired t tests were computed for each subject. One-sided P values were calculated because we hypothesized a decrease in HSA, particularly for subjects taking gabapentin. For the HSA the significance level of each test was Bonferroni-adjusted at 0.05/ Correlations between pre- and on-treatment HSA and VAS scores for the same patient were examined using a standard correlation test; a correlation coefficient of zero indicated changes in the values of one variable did not affect the values of the other variable. The data contained imputed values as replacements for missing observations; a nearest-neighbor hot deck imputation method was used to estimate these values. 14,15 In hot deck imputation, missing data are replaced by values taken from complete records of subjects with characteristics similar to the subject for whom data are missing. 14,15 Two mixed-effects models, one with HSA as the dependent variable and one with VAS as the dependent variable, were run on the imputed data using the PROC MIXED procedure of SAS V8.2 (SAS Institute, Cary, NC). These results were calculated using data collected in the first 24 hours, as these were available from most subjects. The fixed effects were time of measurement, treatment group (i.e., patients randomized to gabapentin or to placebo), treatment phase (i.e., pretreatment or on-treatment), and an interaction term of treatment group and treatment phase. Subjects were included as nested random effects because they represented a random sample from a population of patients with chronic pruritus secondary to liver disease, and the effects due to the subjects per se were dependent on the effect due to the treatment group. The data were log-transformed to stabilize the variance among groups and to make the distribution of the HSA measurement normal. In the mixedeffects model differences were considered significant at P less than.05. Results Dermatological Evaluation. None of the patients had a dermatological disease associated with pruritus. Psychiatric Evaluation. Data on the full psychiatric evaluation were available for 13 of the 16 patients. One patient (patient 11) did not have an evaluation performed because she was moving to another state, and the admission could not be coordinated with the psychiatric exam, 1 patient (patient 5) dropped out of the study prior to the exam, and the exam of another patient (patient 4) was incomplete and not helpful, as only data from the SCID were available. The results of the full 17-item Hamilton scale, which includes items intrinsic to medical conditions (i.e. fatigue, sleep, and concern about health), showed that 8 patients (patients 2, 3, 7, 10, 12, 13, 15, and 16 [62%]) scored in the range of mild depression, 3 (patients 1, 9, and 14 [23%]) in the range of moderate depression, and 2 (patients 6 and 8 [15%]) in the range of no to minimal depression (0-7); however, the scores of the latter group were 6-7, which might be considered minimal rather than absent depression. When the items relating to medical conditions were omitted, 7 patients (patient 1, 2, 7, 9, 12, 13, and 14 [54%]) scored in the range of mild depression, none in the range of moderate depression, and 6 (patients 3, 6, 8, 10, 15, and 16 [46%]) in the range of no to minimal depression. Four subjects remained in the mildly depressed range despite receiving antidepressant treatment (patient 9 received doxepin; patient 12, Lexapro; patient 13, Lamictal, Seroquel, and Ambien; and patient 14, Celexa), whereas one subject (patient 16) who went from moderate depression to none was on one antidepressant (Zoloft) and previously had been on another one (Celexa), suggesting she was considered to be depressed at one point. On the SCID, one patient (patient 14) had major depressive disorder with atypical features. The remainder of the patients were diagnosed with a mood disorder because of a general medical condition, 8 with depressive features (patients 2, 3, 6, 8, 10, 12, 15, and 16), and 4 with major depression-like episodes (patients 1, 7, 9, and 13). The results of the psychiatric evaluations suggested that liver disease and pruritus might have contributed to the depressive symptomatology of the subjects. Side Effects Associated with Gabapentin and Placebo. On gabapentin, patient 1 experienced a rise in her serum bilirubin at the end of the study period, interpreted as resulting from progression of her disease (PBC), which was confirmed by histology after she had a liver transplantation several months later. On gabapentin, patient 2 experienced fatigue, patient 4 dizziness, patient 7 worsening
4 1320 BERGASA ET AL. HEPATOLOGY, November 2006 Table 1. Effect of Gabapentin or Placebo on the Perception of Pruritus as Reported Orally and on HSA and VAS Patient No. Oral Report HSA Mean Difference VAS Mean Difference Patients randomized to gabapentin 1 No relief (0.361) (0.002) 14 No relief (0.002) (0.033) 16 Initial relief/no relief in the last days of treatment 8.2 (0.382)* (0.005) 2 Relief at times (0.027) (0.077) 6 Some relief (0.019) (0.000) 10 Relief (0.011) (0.098) 12 Relief Technical failure (pre) (0.012) Patients randomized to placebo 3 Relief most of the time (0.000) (0.000) 4 Relief (0.025) (0.000) 7 No relief initially/relief in the last days of treatment (0.000) (0.001) 11 Relief (0.085) (0.717) 15 Relief (0.183) (0.034) 13 No relief Technical failure (pre) (0.013) Abbreviations: HAS, hourly scratching activity; VAS, visual analog score. *Based on 10 measurements. All others based on measurements. P values in parentheses; statistical significance defined as P.004; a negative number indicates that the treatment measurement was higher (i.e., worse) than that at baseline. symptoms of carpal tunnel syndrome, patient 8 vomiting, and patient 16 dizziness on increasing dose and a fluctuating rise in serum creatinine. Gabapentin was discontinued in these patients. On placebo, patient 3 developed fatigue and leukopenia, and patient 7 developed symptoms of carpal tunnel syndrome. Effect of Study Drug on Pruritus of Cholestasis. The results and the subjects oral reports of their perception of pruritus after 4 weeks of treatment are given in Table 1. Patients 4 and 7, who took gabapentin after completing treatment with placebo, did not continue on gabapentin, and patients 3, 11, 10, and 15 remained on gabapentin; patient 3 underwent liver transplantation several months later because of progression of her disease (PSC). Patient 12, who had stage IV PBC, underwent liver transplantation, as hepatocellular carcinoma was suspected from screening. Three of the 16 patients dropped out of the study one (patient 5) prior to randomization because she did not wish to remain hospitalized for baseline evaluation, one (patient 8) on day 2 because of side effects, and one (patient 9), who had been randomized to placebo, because of persistent severe pruritus within 2 weeks of randomization. All the patients who completed the 4-week study under code went up to the dose of 2,400 mg per day except patients 15 and 16, who took 1,200 and 1,500 mg daily, respectively. Results of Statistical Analysis. The graphs for baseline HSA (Fig. 2A,B) show that scratching activity of the patients randomized to gabapentin (Fig. 2A) was higher than that of the patients randomized to placebo (Fig. 2B). The scratching activity of the patients on gabapentin did not decrease (Fig. 3A); in contrast, the scratching activity of the patients on placebo was near zero (Fig. 3B). The group randomized to gabapentin, however, seemed to have higher HSA at baseline than the group randomized to placebo, which might have given the placebo treatment some advantage. These observations are supported by the results of the statistical tests reported in Table 1. Correlations between HSA and VAS scores at baseline and on treatment varied from 0.23 to 0.97, suggesting the VAS correlated poorly with HSA. In addition, there was no relationship between baseline and on-treatment HSA or between baseline and on-treatment VAS, as correlations ranged from 0.3 to 0.7 for both variables. Analysis of the imputed log-transformed HSA data showed the treatment group and the interaction of the treatment group with the treatment phase were significant (P.013 and.026, respectively); however, the effects of the subjects and of the treatment phase per se were not significant (P.2 and.16). This implies a detectable difference in HSA measurements between those subjects on gabapentin and those on placebo without consideration of the phase (i.e., baseline or on treatment) at which the measurement was taken. This result may reflect the difference between the treatment groups in the baseline measurements of the subjects (Fig. 2A-B); however, the difference was also affected by the treatment phase (i.e., pre- or on-treatment) during which the measurement was taken. Table 2 gives the means with standard deviations of the non-transformed HSA for the 4 groups: baseline prior
5 HEPATOLOGY, Vol. 44, No. 5, 2006 BERGASA ET AL Fig. 2. Mean baseline hourly scratching activity (HSA) in patients subsequently randomized to gabapentin (A) and to placebo (B). Fig. 3. Mean hourly scratching activity (HSA) in patients randomized to gabapentin (A) and to placebo (B) after at least 4 weeks on treatment. to randomization to gabapentin and on gabapentin, and baseline prior to randomization to placebo and on placebo; these data helped to determine the direction of the effect. It can be appreciated that the significance of the interaction effect came from 2 sources: a large increase in the mean HSA associated with treatment with gabapentin and a large decrease in the mean HSA associated with treatment with placebo. Discussion Our findings indicate that gabapentin does not have a therapeutic advantage over placebo for patients with the pruritus of cholestasis, some of whom were refractory to drugs used to treat this symptom; in fact, this drug appears to worsen pruritus. In contrast, treatment with placebo was associated with relief from pruritus for most patients by all measures used to assess this symptom. The correlations between baseline HSA and VAS were low, suggesting that the VAS of the pruritus of cholestasis is an unreliable predictor of HSA, in general, as was found in a previous study. 9 We also found that the time at which HSA and VAS was recorded influenced the results; accordingly, a VAS of pruritus obtained at random may not be interpretable. The most stunning results of this study can be visually appreciated from Figs. 2 and 3. It is clear that patients on placebo (Fig. 3B) scratched less than those on gabapentin (Fig. 3A), indicating that the placebo effect resulted not only in subjective improvement, but also in a change in Table 2. Nontransformed Mean Hourly Scratching Activity* by Treatment Phase Group Hourly Scratching Activity [mean (SD)] Pre gabapentin (89.35) On gabapentin (125.09) Pre placebo (99.52) On placebo (41.23) *Hourly scratching activity is expressed in arbitrary units.
6 1322 BERGASA ET AL. HEPATOLOGY, November 2006 behavior. In contrast, some patients on gabapentin reported no relief of pruritus and scratched more and had a higher mean VAS, some significantly so, than at baseline. A question arises: did gabapentin interfere with the placebo effect? In trying to address this question, current ideas on the placebo response should be discussed. The placebo effect results from at least 2 types of changes, subjective and physiological (i.e., changes in neurotransmission). 16 In this context, studies that used positron emission tomography demonstrated that the mechanism mediating the placebo response in Parkinson s disease is associated with a release of dopamine in response to the activation of the nigostriatal dopamine system by the placebo intervention. 17 The association of a placebo intervention with dopamine release raises another question: can dopamine exert an antipruritic effect? The answer is yes. Evidence suggests that the pruritus of cholestasis is mediated, at least in part, by increased central opioidergic tone, which is the reason this type of pruritus is treated with opiate antagonists. 9-12,18-21 It has been shown that the pruritus resulting from the central administration of morphine (i.e., pruritus secondary to increased opioidergic tone), which may be analogous to the pruritus of cholestasis, can be relieved effectively by droperidol, 22,23 a short-acting neuroleptic agent with affinity for the D2 dopamine receptor. 24 Initial treatment with neuroleptics, which may be analogous to the acute effect of droperidol administration, is associated with activation of dopamine neurons and enhanced dopamine release. 24 Accordingly, if droperidol decreases central, morphine-induced pruritus, endogenous dopamine release may decrease central, opioid-mediated pruritus (i.e., as it is hypothesized to occur in cholestasis). Thus, activation of the nigrostriatal system (i.e., dopamine release) by a placebo intervention may mediate a decrease in pruritus by signals transmitted via the neural networks that connect the basal ganglia, which release dopamine, with the cerebral cortex, 25,26 where itch stimuli and the urge to scratch are represented Having considered the role of dopamine in the placebo effect, it does appear that gabapentin could have interfered with the placebo effect. Animal studies 30,31 have documented that gabapentin blocks dopamine release from the basal ganglia (i.e., the striatum) and from the nucleus accumbens, preventing dopamine-mediated behavior. 31 Accordingly, it seems plausible that gabapentin, by virtue of its ability to block dopamine release, may have interfered with dopamine-mediated relief of pruritus triggered by a placebo intervention. It is evident that in this study gabapentin was not a placebo intervention; however, it is the expectation of relief and, likely, the degree of that expectation that appear to mediate, at least in part, the release of dopamine that occurs with a placebo intervention. 17,32 Thus, patients with pruritus expected relief, but this expectation, which mediates the placebo effect and would have resulted in dopamine release and hence an antipruritic effect, was blocked by gabapentin. This is our hypothesis. The dichotomous effect of gabapentin in this study can be explained by the differences among the patients in the threshold for activation of neurotransmission and in the degree of expectation. 17,32 A high expectation of relief may have resulted in a strong stimulus for dopamine release, which may not have been completely blocked by gabapentin at the doses used in this study, allowing enough dopamine to mediate neurotransmission with the result of some relief from the pruritus. In contrast, a low expectation of relief may have resulted in a weak stimulus for dopamine release, which could have been blocked by the gabapentin at the doses used, preventing dopamine-mediated relief of pruritus. This interpretation suggests that patients expectation is an important question to address in studies of pruritus; unfortunately, information on the expectations of relief by the patients in our study was not sought a priori. The small number of patients was a limitation of this study; however, the strong placebo effect observed has focused our attention on the antipruritic effects of placebo in the pruritus of cholestasis and emphasizes that any intervention on pruritus may be difficult to interpret without some objective measure of change. As documented by the psychiatric evaluation, the pruritus of cholestasis has a negative impact on the emotional life of patients, and it can be an indication for liver transplantation even in the absence of liver failure. 33,34 These facts stress the importance of exploring why this symptom continues to escape understanding, contributing to the lack of consistently effective and specific treatments. In summary, in this study gabapentin was not associated with a significant amelioration of the pruritus secondary to liver disease; in fact, on average, it worsened the pruritus and the scratching behavior. Several scientific questions have emerged from this experience, including the role of dopamine neurotransmission in the treatment of pruritus and on the neurophysiologic basis for the placebo effect on the pruritus of cholestasis. Acknowledgment: The authors thank Glen Gillen, MPA, OTR, Sabrina Salvant, MS, MPH, Jane Bear- Lehman, PhD, OTR, FAOTA, Jacqueline Brown, MS, OTR/L, CHT, and Batsheva Meisels, OTR/L, CHT, from Occupational Therapy for making the orthotic devices, the staff of the Research Pharmacy and the GCRC for facilitating the conduct of the study, Erica Torres for her administrative work, and Howard J. Worman, MD, for
7 HEPATOLOGY, Vol. 44, No. 5, 2006 BERGASA ET AL monitoring the study. Dr. Bergasa is grateful to Thomas Talbot, Engineer, for his continued support and advice on the use of the scratching activity monitoring system. References 1. Jones EA, Bergasa NV. The pruritus of cholestasis. HEPATOLOGY 1999;29: Bergasa NV. The pruritus of cholestasis. J Hepatol 2005;43: Magerl W. Neural mechanisms of itch sensation. IASP Newsletter 1996; Sept-Oct. 4. Gustafsson H, Flood K, Berge OG, Brodin E, Olgart L, Stiller CO. Gabapentin reverses mechanical allodynia induced by sciatic nerve ischemia and formalin-induced nociception in mice. Exp Neurol 2003;182: Rodrigues-Filho R, Campos MM, Ferreira J, Santos AR, Bertelli JA, Calixto JB. Pharmacological characterisation of the rat brachial plexus avulsion model of neuropathic pain. Brain Res 2004;1018(2): Bueller HA, Bernhard JD, Dubroff LM. Gabapentin treatment for brachioradial pruritus. J Eur Acad Dermatol Venereol 1999;13: Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatr 1960;23: Williams JB, Gibbon M, First MB, Spitzer RL, Davies M, Borus J, et al. The Structured Clinical Interview for DSM-III-R (SCID). II. Multisite test-retest reliability. Arch Gen Psychiatry 1992;49: Bergasa NV, Talbot TL, Alling DW, Schmitt JM, Walker EC, Baker BL, et al. A controlled trial of naloxone infusions for the pruritus of chronic cholestasis. Gastroenterology 1992;102: Bergasa NV, Talbot TL, Schmitt JP, Alling DW, Swain MG, Turner M, et al. Open label trial of oral nalmefene therapy for the pruritus of cholestasis. HEPATOLOGY 1998;27: Bergasa NV, Alling DW, Talbot TL, Swain MG, Yurdaydin C, Schmitt JM, et al. Naloxone ameliorates the pruritus of cholestasis: results of a double-blind randomized placebo-controlled trial. Ann Intern Med 1995; 123: Bergasa NV, Alling DW, Talbot TL, Wells M, Jones EA. Oral nalmefene therapy reduces scratching activity due to the pruritus of cholestasis: a controlled study. J Am Acad Dermatol 1999;41: Talbot TL, Schmitt JM, Bergasa NV, Jones EA, Walker EC. Application of piezo film technology for the quantitative assessment of pruritus. Biomed Instrum Technol 1991;25: Little R, Rubin D. Statistical Analysis with Missing Data. 2nd ed. New York: Wiley Interscience, McGee M, Bergasa NV. Imputing Missing Data in Clinical Pilot Studies. Technical Report. Dallas, TX: Southern Methodist University, Kradin RL. The placebo response: its putative role as a functional salutogenic mechanism of the central nervous system. Perspect Biol Med 2004; 47: de la Fuente-Fernandez R, Ruth TJ, Sossi V, Schulzer M, Calne DB, Stoessl AJ. Expectation and dopamine release: mechanism of the placebo effect in Parkinson s disease. Science 2001;293: Carson KL, Tran TT, Cotton P, Sharara AI, Hunt CM. Pilot study of the use of naltrexone to treat the severe pruritus of cholestatic liver disease. Am J Gastroenterol 1996;91: Wolfhagen FHJ, Sternieri E, Hop WCJ, Vitale G, Bertolotti M, van Buuren HR. Oral naltrexone treatment for cholestatic pruritus: a doubleblind, placebo-controlled study. Gastroenterology 1997;113: Neuberger J, Jones EA. Liver transplantation for intractable pruritus is contraindicated before an adequate trial of opiate antagonist therapy. Eur J Gastroenterol Hepatol 2001;13: Terg R, Coronel E, Sorda J, Munoz AE, Findor J. Efficacy and safety of oral naltrexone treatment for pruritus of cholestasis, a crossover, double blind, placebo-controlled study. J Hepatol 2002;37: Horta ML, Ramos L, Goncalves ZR. The inhibition of epidural morphineinduced pruritus by epidural droperidol. Anesth Analg 2000;90: Horta ML, Ramos L, Goncalves Zda R, de Oliveira MA, Tonellotto D, Teixeira JP, et al. Inhibition of epidural morphine-induced pruritus by intravenous droperidol. The effect of increasing the doses of morphine and of droperidol. Reg Anesth 1996;21: Baldessarini RJ. Drugs and the treatment of psychiatric disorders. In: Molinoff PB, Ruddon RW, eds. The Pharmacological Basis of Therapeutics. New York: McGraw-Hill, 1996: Coté L, Crutcher M. The basal ganglia. In: Kandel ER, Scwartz JH, Jessell TM, eds. Principles of Neural Science. Norwalk: Appleton and Lange, 1991: McFarland NR, Haber SN. Thalamic relay nuclei of the basal ganglia form both reciprocal and nonreciprocal cortical connections, linking multiple frontal cortical areas. J Neurosci 2002;22: Hsieh JC, Hagermark O, Stahle-Backdahl M, Ericson K, Eriksson L, Stone-Elander S, et al. Urge to scratch represented in the human cerebral cortex during itch. J Neurophysiol 1994;72: Drzezga A, Darsow U, Treede RD, Siebner H, Frisch M, Munz F, et al. Central activation by histamine-induced itch: analogies to pain processing: a correlational analysis of O-15 H2O positron emission tomography studies. Pain 2001;92(1-2): Mochizuki H, Tashiro M, Kano M, Sakurada Y, Itoh M, Yanai K. Imaging of central itch modulation in the human brain using positron emission tomography. Pain 2003;105(1-2): Reimann W. Inhibition by GABA, baclofen and gabapentin of dopamine release from rabbit caudate nucleus: are there common or different sites of action? Eur J Pharmacol 1983;94: Andrews N, Loomis S, Blake R, Ferrigan L, Singh L, McKnight AT. Effect of gabapentin-like compounds on development and maintenance of morphine-induced conditioned place preference. Psychopharmacology (Berl) 2001;157: Wager TD, Rilling JK, Smith EE, Sokolik A, Casey KL, Davidson RJ, et al. Placebo-induced changes in FMRI in the anticipation and experience of pain. Science 2004;303: Elias E. Liver Transplantation. J Roy Coll Phys London 1993;27: Jones EA, Neuberger J, Bergasa NV. Opiate antagonist therapy for the pruritus of cholestasis: the avoidance of opioid withdrawal-like reactions. QJM 2002;95:
Analysis of a Pilot Study for Amelioration of. Itching in Liver Disease: When is a Failed Trial not a Failure? Monnie McGee* & Nora V.
Analysis of a Pilot Study for Amelioration of Itching in Liver Disease: When is a Failed Trial not a Failure? Monnie McGee* & Nora V. Bergasa** *Department of Statistical Science, Southern Methodist University
More informationImputing Missing Data in Clincal Pilot Studies
Imputing Missing Data in Clincal Pilot Studies Monnie McGee* & Nora Bergasa *Department of Statistical Science, Southern Methodist University Dallas, TX 75275 Division of Hepatology, SUNY Downstate Medical
More informationProlonged Follow-Up of Patients in the U.S. Multicenter Trial of Ursodeoxycholic Acid for Primary Biliary Cirrhosis
American Journal of Gastroenterology ISSN 0002-9270 C 2004 by Am. Coll. of Gastroenterology doi: 10.1111/j1572-0241.2004.04047.x Published by Blackwell Publishing Prolonged Follow-Up of Patients in the
More informationDownloaded from umj.umsu.ac.ir at 7: on Wednesday October 3rd 2018
-. % : PDN (PDN). Index case.. : ( ) mg Visual analogue scale (VAS)... : - % %. (). (QOL).. safe : - E-mail: Hamidnoshad1@yahoo.com : :.() ) ( ). ( C-fibers.() modified () - - - 6-7 - () () () ().().().()
More informationIntractable pruritus is encountered frequently
Brief reports 527 Butorphanol for treatment of intractable pruritus Aerlyn G. Dawn, MD, MBA, a and Gil Yosipovitch, MD a,b Winston-Salem, North Carolina Severe chronic itch and intractable pruritus are
More informationClinical Efficacy and Safety of Naltrexone Combination Therapy in Older Patients with Severe Pruritus
pissn 1013-9087ㆍeISSN 2005-3894 Ann Dermatol Vol. 28, No. 2, 2016 http://dx.doi.org/10.5021/ad.2016.28.2.159 ORIGINAL ARTICLE Clinical Efficacy and Safety of Naltrexone Combination Therapy in Older Patients
More informationSponsor. Generic drug name. Trial indication(s) Protocol number. Protocol title. Phase of Drug Development. Study Start/End Dates
Sponsor Novartis Generic drug name SAB378 [Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone] Trial indication(s) Postherpetic neuralgia (PHN) Protocol number CSAB378A2201 Protocol title A multicenter,
More informationThe Role of Ondansetron in the Management of Cholestatic or Uremic PruritusdA Systematic Review
Vol. No. 5 November 2012 Journal of Pain and Symptom Management 725 Review Article The Role of Ondansetron in the Management of Cholestatic or Uremic PruritusdA Systematic Review Timothy H.M. To, BMBS,
More informationImpact of Chronic Liver Disease and Cirrhosis on Health Utilities Using SF-6D and the Health Utility Index
LIVER TRANSPLANTATION 14:321-326, 2008 ORIGINAL ARTICLE Impact of Chronic Liver Disease and Cirrhosis on Health Utilities Using SF-6D and the Health Utility Index Amy A. Dan, 1,2 Jillian B. Kallman, 1,2
More informationOut-patient albumin dialysis for cholestatic patients with intractable pruritus
Alimentary Pharmacology and Therapeutics Out-patient albumin dialysis for cholestatic patients with intractable pruritus P. Leckie*, G. Tritto*, R. Mookerjee*, N. Davies*, D. Jones & R. Jalan* *Liver Failure
More informationPAIN. Physiology of pain relating to pain management
PAIN Physiology of pain relating to pain management What is pain? An unpleasant sensory and emotional experience associated with actual or potential tissue damage. (Melzac and Wall) The generation of pain
More informationMorning Report Presentation. Sarah Hughes, MD January 11, 2005
Morning Report Presentation Sarah Hughes, MD January 11, 2005 Primary Biliary Cirrhosis! PBC is a chronic, progressive, cholestatic liver disease of unknown cause that usually affects middle-aged women
More informationPrimary Biliary Cholangitis
Primary Biliary Cholangitis What is primary biliary cholangitis? Primary biliary cholangitis (PBC), formerly known as primary biliary cirrhosis, is a chronic liver disease. When a person has PBC, the immune
More informationPrognosis of untreated Primary Sclerosing Cholangitis (PSC) Erik Christensen Copenhagen, Denmark
Prognosis of untreated Primary Sclerosing Cholangitis (PSC) Erik Christensen Copenhagen, Denmark Study of Prognosis of PSC Difficulties: Disease is rare The duration of the course of disease may be very
More informationPediatric PSC A children s tale
Pediatric PSC A children s tale September 8 th PSC Partners seeking a cure Tamir Miloh Assistant Professor Pediatric Hepatology Mount Sinai Hospital, NY Incidence Primary Sclerosing Cholangitis (PSC) ;
More informationThis was a randomized, double-blind, placebo-controlled, fixed-dose, parallel-group study.
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationFactorial Study Design 07/18/12
Disclaimer: The following information is fictional and is only intended for the purposes of illustrating key concepts for results data entry in the Protocol Registration System (PRS). Example Factorial
More informationMorphiDex (MS:DM) Double-Blind, Multiple-Dose Studies In Chronic Pain Patients
Vol. 19 No. 1(Suppl.) January 2000 Journal of Pain and Symptom Management S37 Proceedings Supplement NMDA-Receptor Antagonists: Evolving Role in Analgesia MorphiDex (MS:DM) Double-Blind, Multiple-Dose
More informationSwitching antipsychotics: Basing practice on pharmacology & pharmacokinetics
Switching antipsychotics: Basing practice on pharmacology & pharmacokinetics John Donoghue Liverpool L imagination est plus important que le savoir Albert Einstein Switching Antipsychotics: Objectives
More informationWhy do we itch and scratch? Radhika Bali 6 th Year Medical Student University of Cambridge
Why do we itch and scratch? Radhika Bali 6 th Year Medical Student University of Cambridge Introduction Itch is an increasingly common symptom presenting in both dermatology and primary care, which may
More informationSetting The setting was secondary care. The economic study was carried out in the USA.
A prospective, randomized trial of intrathecal injection vs. epidural infusion in the selection of patients for continuous intrathecal opioid therapy Anderson V C, Burchiel K J, Cooke B Record Status This
More informationMY DISCUSSION GUIDE. Personalize your treatment plan for primary biliary cholangitis (PBC).
I am not on OCALIVA (obeticholic acid) MY DISCUSSION GUIDE Personalize your treatment plan for primary biliary cholangitis (PBC). This guide is not intended to replace the advice of your healthcare team.
More informationPrimary Biliary Cirrhosis
Primary Biliary Cirrhosis What is Primary Biliary Cirrhosis? Primary biliary cirrhosis (PBC) is a chronic liver disease resulting from progressive destruction of the bile ducts in the liver called the
More informationDrugs 101: Behavioral Pharmacology
Drugs 101: Behavioral Pharmacology Eb Blakely, Ph.D., BCBA-D Quest, Inc./Florida Institute of Technology Drug Facts Drug effects are dose-dependent Drugs effects are time-dependent Drugs are toxic at high
More informationPrimary Sclerosing Cholangitis and Cholestatic liver diseases. Ahsan M Bhatti MD, FACP Bhatti Gastroenterology Consultants
Primary Sclerosing Cholangitis and Cholestatic liver diseases Ahsan M Bhatti MD, FACP Bhatti Gastroenterology Consultants I have nothing to disclose Educational Objectives What is PSC? Understand the cholestatic
More informationAn overview of Medication Assisted Treatment (MAT) and acute pain management on MAT
An overview of Medication Assisted Treatment (MAT) and acute pain management on MAT Goals of Discussion Recognize opioid use disorder (OUD) Discuss the pharmacology of medication assisted treatments (MAT)
More informationControlled-Release Oxycodone Alone or Combined with Gabapentin for Management of Malignant Neuropathic Pain
80 Chin J Cancer Res 22(1):80-86, 2010 www.springerlink.com Original Article Controlled-Release Oxycodone Alone or Combined with Gabapentin for Management of Malignant Neuropathic Pain Xiao-mei Li 1*,
More informationNew data show sustained 5-year benefit of Neupro (Rotigotine Transdermal System) for symptoms of Restless Legs Syndrome
New data show sustained 5-year benefit of Neupro (Rotigotine Transdermal System) for symptoms of Restless Legs Syndrome Latest safety and efficacy results for rotigotine in the treatment of moderate to
More informationLiver Transplantation for Alcoholic Liver Disease in the United States: 1988 to 1995
Liver Transplantation for Alcoholic Liver Disease in the United States: 1988 to 1995 Steven H. Belle, Kimberly C. Beringer, and Katherine M. Detre T he Scientific Liver Transplant Registry (LTR) was established
More informationOverview of PSC Jayant A. Talwalkar, MD, MPH Associate Professor of Medicine Mayo Clinic Rochester, MN
Overview of PSC Jayant A. Talwalkar, MD, MPH Associate Professor of Medicine Mayo Clinic Rochester, MN 2012 Annual Conference PSC Partners Seeking a Cure May 5, 2012 Primary Sclerosing Cholangitis Multifocal
More informationSupplementary Online Content
Supplementary Online Content Lam RW, Levitt AJ, Levitan RD, et al. Efficacy of bright light treatment, fluoxetine, and the combination in patients with nonseasonal major depressive disorder: a randomized
More informationMAPS Study MP-10 1 Study Synopsis UK April 18, 2011
MAPS Study MP-10 1 Study Synopsis A Randomized, Triple-Blind, Phase 2 Pilot Study with an Open-Label Lead-in Comparing 3 Different Doses of MDMA in Conjunction with Manualized Psychotherapy in 20 Subjects
More informationNeuropathic Pain Treatment Guidelines
Neuropathic Pain Treatment Guidelines Background Pain is an unpleasant sensory and emotional experience that can have a significant impact on a person s quality of life, general health, psychological health,
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Ocaliva (obeticholic acid) Page 1 of 6 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Ocaliva (obeticholic acid) Prime Therapeutics will review Prior Authorization
More informationNew insights in pathogenesis and therapy of primary biliary cholangitis. Keith D. Lindor Dean Professor of Medicine
New insights in pathogenesis and therapy of primary biliary cholangitis Keith D. Lindor Dean Professor of Medicine OUTLINE PBC Epidemiology Diagnosis Treatment Incidence of PBC and PSC Trends Boonstra
More informationNociceptive Pain. Pathophysiologic Pain. Types of Pain. At Presentation. At Presentation. Nonpharmacologic Therapy. Modulation
Learning Objectives Effective, Safe Analgesia An Approach to Appropriate Outpatient Chronic Pain Treatment By the end of this presentation, participants will be able to: Identify multiple factors that
More informationIntron A (interferon alfa-2b) with ribavirin, (Moderiba, Rebetol, Ribasphere, RibaTab, ribavirin tablets/capsules - all strengths)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.06 Subject: Intron A Ribavirin Page: 1 of 6 Last Review Date: March 18, 2016 Intron A Ribavirin Description
More informationIdiopathic adulthood ductopenia manifesting as jaundice in a young male
Idiopathic adulthood ductopenia manifesting as jaundice in a young male Deepak Jain*,1, H. K. Aggarwal 1, Avinash Rao 1, Shaveta Dahiya 1, Promil Jain 2 1 Department of Medicine, Pt. B.D. Sharma University
More information2. Chapter 2: Eligibility
2.1 Overview of Approach and Goals 2. Chapter 2: Eligibility The goal is to randomize 1375 participants over 18 years of age who meet DSM-IV criteria for alcohol dependence and are abstinent for a minimum
More informationDiagnosis & Management of Major Depression: A Review of What s Old and New. Cerrone Cohen, MD
Diagnosis & Management of Major Depression: A Review of What s Old and New Cerrone Cohen, MD Why You re Treating So Much Mental Health 59% of Psychiatrists Are Over the Age of 55 AAMC 2014 Physician specialty
More informationReview Article Management of Pruritus in Chronic Liver Disease
Dermatology Research and Practice Volume 2015, Article ID 295891, 5 pages http://dx.doi.org/10.1155/2015/295891 Review Article Management of Pruritus in Chronic Liver Disease Angeline Bhalerao 1 and Gurdeep
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationPDF of Trial CTRI Website URL -
Clinical Trial Details (PDF Generation Date :- Sat, 03 Nov 2018 09:24:50 GMT) CTRI Number Last Modified On 10/06/2013 Post Graduate Thesis Type of Trial Type of Study Study Design Public Title of Study
More informationThe Nervous System. Chapter 4. Neuron 3/9/ Components of the Nervous System
Chapter 4 The Nervous System 1. Components of the Nervous System a. Nerve cells (neurons) Analyze and transmit information Over 100 billion neurons in system Four defined regions Cell body Dendrites Axon
More informationClinical Trial Results Summary Study EN
Study Number: EN3288-113 Title of Study: A Double-blind, Dose-Ranging, Pilot Study to Evaluate the Safety, Subjective Effects, and Pharmacokinetics of Oxymorphone Hydrochloride in Healthy Subjects Who
More informationMain Questions. Why study addiction? Substance Use Disorders, Part 1 Alecia Schweinsburg, MA Abnromal Psychology, Fall Substance Use Disorders
Substance Use Disorders Main Questions Why study addiction? What is addiction? Why do people become addicted? What do alcohol and drugs do? How do we treat substance use disorders? Why study addiction?
More informationAcute Pain NETP: SEPTEMBER 2013 COHORT
Acute Pain NETP: SEPTEMBER 2013 COHORT Pain & Suffering an unpleasant sensory & emotional experience associated with actual or potential tissue damage, or described in terms of such damage International
More informationPBC features and management in the era of UDCA and Budesonide
PBC features and management in the era of UDCA and Budesonide Raoul Poupon, MD Université P&M Curie, AP-Hôpitaux de Paris, Inserm, Paris, France The changing pattern of PBC Over the last 2 decades: More
More informationForward-looking Statements
Forward-looking Statements This presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationSummary ID#7029. Clinical Study Summary: Study F1D-MC-HGKQ
CT Registry ID# 7029 Page 1 Summary ID#7029 Clinical Study Summary: Study F1D-MC-HGKQ Clinical Study Report: Versus Divalproex and Placebo in the Treatment of Mild to Moderate Mania Associated with Bipolar
More informationPresentation and mortality of primary biliary cirrhosis in older patients
Age and Ageing 2000; 29: 305 309 Presentation and mortality of primary biliary cirrhosis in older patients JULIA L. NEWTON 1,DAVID E. JONES 2,JANE V. METCALF 2,JAY B. PARK 2,ALISTAIR D. BURT 2, MARGARET
More informationThe Safety and Efficacy of Ondansetron in the Treatment of Obsessive Compulsive Disorder
Duquesne University Duquesne Scholarship Collection Graduate Student Research Symposium The 4th Annual Graduate Student Research Symposium September 19, 2017 The Safety and Efficacy of Ondansetron in the
More informationTrial No.: RIS-USA-102 Clinical phase: III
SYNOPSIS Trial identification and protocol summary Company: Johnson & Johnson Pharmaceutical Research and Development, a division of Janssen Pharmaceutica, N.V. Finished product: Risperdal Active ingredient:
More informationMY DISCUSSION GUIDE. Get the most out of your OCALIVA treatment.
PBC I am currently taking OCALIVA (obeticholic acid) MY DISCUSSION GUIDE Get the most out of your OCALIVA treatment. This guide is not intended to replace the advice of your healthcare team. All decisions
More informationCholestatic jaundice Chronic kidney disease Iron deficiency +/-anaemia. Hepatoma Diabetes Leukaemia
Pruritis Introduction Pruritis can cause discomfort, frustration, poor sleep, anxiety and depression. Itch may be localised or due to systemic disease. Pruritis in systemic disease is often worse at night.
More informationHangzhou, 15 March Ulrich Beuers Department of Gastroenterology and Hepatology Academic Medical Center University of Amsterdam
Clinical Aspects of Primary Biliary Cirrhosis Hangzhou, 15 March 2008 Ulrich Beuers Department of Gastroenterology and Hepatology Academic Medical Center University of Amsterdam Epidemiology of Primary
More informationChronic Cholestatic Liver Diseases
Chronic Cholestatic Liver Diseases - EASL Clinical Practice Guidelines - Rome, 8 October 2010 Ulrich Beuers Department of Gastroenterology and Hepatology Tytgat Institute of Liver and Intestinal Research
More informationIntron A Hepatitis C. Intron A (interferon alfa-2b) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.05 Subject: Intron A Hepatitis C Page: 1 of 5 Last Review Date: November 30, 2018 Intron A Hepatitis
More informationImproving the Lives of Patients with Liver Diseases
Improving the Lives of Patients with Liver Diseases Corporate Presentation March 2019 Safe Harbor Statement This presentation contains "forward-looking" statements that involve risks, uncertainties and
More informationPrimary Sclerosing Cholangitis Medical Management
Primary Sclerosing Cholangitis Medical Management Kapil Chopra M.D. Assistant Professor of Medicine Division of Transplant Medicine Mayo Clinic Arizona PSC Primary sclerosing cholangitis is a progressive
More informationOCALIVA (obeticholic acid) oral tablet
OCALIVA (obeticholic acid) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy
More informationBuprenorphine Access in California
Buprenorphine Access in California James J. Gasper, PharmD, BCPP Pharmacy Benefits Division Department of Health Care Services james.gasper@dhcs.ca.gov Source: CDPH Vital Statisitics Death Statistical
More informationSingle Technology Appraisal (STA) Obeticholic acid for treating primary biliary cirrhosis ID785
Single Technology Appraisal (STA) Obeticholic acid for treating primary biliary cirrhosis ID785 Response to consultee and commentator comments on the draft remit and draft scope (pre-referral) Comment
More informationUnderstanding Addiction and Its Impact on the Brain. SDSMA Webinar Matthew Stanley, DO
Understanding Addiction and Its Impact on the Brain SDSMA Webinar Matthew Stanley, DO Estimated Economic Cost to Society Due to Substance Abuse and Addiction: Illegal drugs: Alcohol: Tobacco: $181 billion/year
More informationFrequently Asked Questions FAQS. NeuroStar TMS Therapies
Frequently Asked Questions FAQS NeuroStar TMS Therapies Provided by Dr Terrence A. Boyadjis MD 790 E Market Street Suite 245 West Chester, PA 19382 610.738.9576 FAQS About TMS Therapies Page 1 NeuroStar
More informationLIVER TRANSPLANTATION FOR OVERLAP SYNDROMES OF AUTOIMMUNE LIVER DISEASES
LIVER TRANSPLANTATION FOR OVERLAP SYNDROMES OF AUTOIMMUNE LIVER DISEASES No conflict of interest Objectives Introduction Methods Results Conclusions Objectives Introduction Methods Results Conclusions
More informationLiving Donor Liver Transplantation Patients Follow-up : Health-related Quality of Life and Their Relationship with the Donor
Showa Univ J Med Sci 29 1, 9 15, March 2017 Original Living Donor Liver Transplantation Patients Follow-up : Health-related Quality of Life and Their Relationship with the Donor Shinji IRIE Abstract :
More informationSponsor / Company: Sanofi Drug substance(s): SAR (iniparib)
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More information... SELECTED ABSTRACTS...
... SELECTED ABSTRACTS... The following abstracts, from medical journals containing literature on irritable bowel syndrome, were selected for their relevance to this supplement. A Technical Review for
More informationIntron A (interferon alfa-2b) with ribavirin, (Copegus, Moderiba, Rebetol, Ribapak, Ribasphere, RibaTab, ribavirin tablets/capsules - all strengths)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Intron A Ribavirin Page: 1 of 5 Last Review Date: November 30, 2018 Intron A Ribavirin Description
More informationThe Effect of Pramipexole on Depressive Symptoms in Parkinson's Disease.
Kobe J. Med. Sci., Vol. 56, No. 5, pp. E214-E219, 2010 The Effect of Pramipexole on Depressive Symptoms in Parkinson's Disease. NAOKO YASUI 1, KENJI SEKIGUCHI 1, HIROTOSHI HAMAGUCHI 1, and FUMIO KANDA
More informationThornton Natural Healthcare s Better Health News
November, 2010 Volume 5, Issue 11 Special Interest Articles: Melatonin and cluster headaches Toxic mushrooms and lipoic acid Food sensitivity and migraines Magnesium and headaches Vitamin D and pneumonia
More informationMEDICAL POLICY SUBJECT: KETAMINE INFUSION THERAPY FOR THE TREATMENT OF CHRONIC PAIN SYNDROMES POLICY NUMBER: CATEGORY: Technology Assessment
Clinical criteria used to make utilization review decisions are based on credible scientific evidence published in peer reviewed medical literature generally recognized by the medical community. Guidelines
More informationSummary ID# Clinical Study Summary: Study F1J-MC-HMDV
CT Registry ID# 7108 Page 1 Summary ID# 7108 Clinical Study Summary: Study F1J-MC-HMDV Duloxetine 60 to 120 mg Once Daily Compared with Placebo in the Prevention of Relapse in Generalized Anxiety Disorder
More informationWhat Is the Real Gain After Liver Transplantation?
LIVER TRANSPLANTATION 15:S1-S5, 9 AASLD/ILTS SYLLABUS What Is the Real Gain After Liver Transplantation? James Neuberger Organ Donation and Transplantation, NHS Blood and Transplant, Bristol, United Kingdom;
More informationClinicalTrials.gov Identifier: NCT Sponsor/company: Sanofi-Aventis. Date: 08/02/ 2008
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: Sanofi-Aventis ClinicalTrials.gov
More informationFDA CLEARS NEUROSTAR TMS THERAPY FOR THE TREATMENT OF DEPRESSION
FOR IMMEDIATE RELEASE FDA CLEARS NEUROSTAR TMS THERAPY FOR THE TREATMENT OF DEPRESSION First and Only Non-systemic and Non-invasive Treatment Cleared for Patients Who Have Not Benefited From Prior Antidepressant
More informationClinical Policy: Lofexidine (Lucemyra) Reference Number: ERX.NPA.88 Effective Date:
Clinical Policy: (Lucemyra) Reference Number: ERX.NPA.88 Effective Date: 07.31.18 Last Review Date: 08.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationFatigue in primary biliary cirrhosis
Gut 998;:0 0 0 Fatigue in primary biliary cirrhosis Department of Medicine K Cauch-Dudek E J Heathcote Department of Psychiatry, Toronto Hospital, University of Toronto, Canada S Abbey D E Stewart Correspondence
More informationDISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics.
DISCLAIMER: Video will be taken at this clinic and potentially used in Project ECHO promotional materials. By attending this clinic, you consent to have your photo taken and allow Project ECHO to use this
More informationACG Clinical Guideline: Primary Sclerosing Cholangitis
ACG Clinical Guideline: Primary Sclerosing Cholangitis Keith D. Lindor, MD, FACG 1, Kris V. Kowdley, MD, FACG 2, and M. Edwyn Harrison, MD 3 1 College of Health Solutions, Arizona State University, Phoenix,
More informationPrimary Biliary Cholangitis
Primary Biliary Cholangitis PBC Foundation (UK) Ltd 6 Hill Street Edinburgh EH2 3JZ Tel: +44 (0) 131 556 6811 info@pbcfoundation.org.uk www.pbcfoundation.org.uk PBC for Healthcare Practitioners Introduction
More informationEvaluation Process for Liver Transplant Candidates
Evaluation Process for Liver Transplant Candidates 2 Objectives Identify components of the liver transplant referral to evaluation Describe the role of the liver transplant coordinator Describe selection
More informationPRODUCT MONOGRAPH ZONALON CREAM 5% GENERIC NAME DOXEPIN HYDROCHLORIDE CREAM 5% THERAPEUTIC CLASSIFICATION TOPICAL ANTIPRURITIC
PRODUCT MONOGRAPH ZONALON CREAM 5% GENERIC NAME DOXEPIN HYDROCHLORIDE CREAM 5% THERAPEUTIC CLASSIFICATION TOPICAL ANTIPRURITIC Valeant Canada LP. Date of Preparation: Montreal, Quebec March 19, 2013 H4R
More informationBuprenorphine pharmacology
Buprenorphine pharmacology Victorian Opioid Management ECHO Department of Addiction Medicine St Vincent s Hospital Melbourne 2018 Page 1 Opioids full, partial, antagonist Full Agonists - bind completely
More informationPBC treatment: the present and future. Maggie Bassendine Professor of Hepatology
PBC treatment: the present and future Maggie Bassendine Professor of Hepatology Primary biliary cirrhosis 20-25yrs OLT/ Death Symptoms: Fatigue, itching, jaundice Autoimmune disease: Focal small bile duct
More informationNORLAND AVENUE PHARMACY PRESCRIPTION COMPOUNDING FOR GENERAL PRACTICE
AUGUST 2011 PRESCRIPTION COMPOUNDING N ORLANDA VENUEP HARMACY. COM We customize individual prescriptions for the specific needs of our patients. INSIDE THIS ISSUE: Hemorrhoids 2 Celiac Disease 3 PRESCRIPTION
More informationProspective assessment of treatment use by patients with personality disorders
Wesleyan University From the SelectedWorks of Charles A. Sanislow, Ph.D. February, 2006 Prospective assessment of treatment use by Donna S. Bender Andrew E. Skodol Maria E. Pagano Ingrid R. Dyck Carlos
More informationGSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationBasics of Restless Legs Syndrome (Willis-Ekbom Disease)
Basics of Restless Legs Syndrome (Willis-Ekbom Disease) Michael H. Silber, M.B.Ch.B. Professor of Neurology Mayo Clinic College of Medicine Objectives Understand how RLS is diagnosed Understand what we
More informationHepatocytes produce. Proteins Clotting factors Hormones. Bile Flow
R.J.Bailey MD Hepatocytes produce Proteins Clotting factors Hormones Bile Flow Trouble.. for the liver! Trouble for the Liver Liver Gall Bladder Common Alcohol Hep C Fatty Liver Cancer Drugs Viruses Uncommon
More informationThe Neuroscience of Addiction: A mini-review
The Neuroscience of Addiction: A mini-review Jim Morrill, MD, PhD MGH Charlestown HealthCare Center Massachusetts General Hospital Disclosures Neither I nor my spouse/partner has a relevant financial relationship
More informationDiagnosis and Management of PBC
Diagnosis and Management of PBC Cynthia Levy, MD, FAASLD University of Miami Miller School of Medicine Miami, Florida 1 Primary Biliary Cholangitis (PBC) Chronic cholestatic liver disease Autoimmune in
More informationManagement of Acute Decompensation of Cirrhosis JOHN O GRADY KING S COLLEGE HOSPITAL
Management of Acute Decompensation of Cirrhosis JOHN O GRADY KING S COLLEGE HOSPITAL Terminology Acute decompensation of cirrhosis - stable patient with sudden deterioration Acute-on-chronic liver failure
More informationOST. Pharmacology & Therapeutics. Leo O. Lanoie, MD, MPH, FCFP, CCSAM, ABAM, MRO
OST Pharmacology & Therapeutics Leo O. Lanoie, MD, MPH, FCFP, CCSAM, ABAM, MRO Disclaimer In the past two years I have received no payment for services from any agency other than government or academic.
More informationAt a Glance. Background Information. Lesson 3 Drugs Change the Way Neurons Communicate
Lesson 3 Drugs Change the Way Neurons Communicate Overview Students build upon their understanding of neurotransmission by learning how different drugs of abuse disrupt communication between neurons. Students
More informationSHARED CARE GUIDELINE FOR THE MANAGEMENT OF PATIENTS ON NALTREXONE FOR OPIOID DEPENDENCE
SHARED CARE GUIDELINE FOR THE MANAGEMENT OF PATIENTS ON NALTREXONE FOR OPIOID DEPENDENCE INDICATION Naltrexone is a pure opiate antagonist licensed as an adjunctive prophylactic therapy in the maintenance
More informationTREATMENT OF PRIMARY BILIARY CIRRHOSIS (PBC)
TREATMENT OF PRIMARY BILIARY CIRRHOSIS (PBC) URSO not indicated Therapy for PBC Difficulties Etiology is uncertain Therapies are based on ideas regarding pathogenesis Present medical therapies have a limited
More informationNew Guidelines for Prescribing Opioids for Chronic Pain
New Guidelines for Prescribing Opioids for Chronic Pain Andrew Lowe, Pharm.D. CAPA Meeting October 6, 2016 THE EPIDEMIC Chronic Pain and Prescription Opioids 11% of Americans experience daily (chronic)
More information